Sunshine Biopharma, Inc.
SBFM
$1.14
$0.032.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 14.53% | -5.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.53% | -5.69% | |||
| Cost of Revenue | 15.73% | 6.48% | |||
| Gross Profit | 11.27% | -27.99% | |||
| SG&A Expenses | 14.13% | -23.92% | |||
| Depreciation & Amortization | 1.43% | -22.24% | |||
| Other Operating Expenses | 6.78% | 2.53% | |||
| Total Operating Expenses | 14.68% | -7.34% | |||
| Operating Income | -15.57% | 15.84% | |||
| Income Before Tax | -25.73% | 28.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.73% | 41.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.73% | 41.90% | |||
| EBIT | -15.57% | 15.84% | |||
| EBITDA | -16.39% | 15.45% | |||
| EPS Basic | 54.82% | 47.76% | |||
| Normalized Basic EPS | 54.82% | 30.13% | |||
| EPS Diluted | 54.82% | 47.76% | |||
| Normalized Diluted EPS | 54.82% | 30.13% | |||
| Average Basic Shares Outstanding | 178.29% | -90.81% | |||
| Average Diluted Shares Outstanding | 178.29% | -90.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||